CSIMarket Company Name, Ticker, Suppliers, else..
 
• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Apollo Endosurgery inc   (APEN)
Other Ticker:  
 

Apollo Endosurgery Inc 's Working Capital Per Sales

APEN's Working Capital and Revenue growth



APEN Working Capital Per Revenue (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Working Capital Change -46.77 % 93.26 % 103.34 % 101.75 % 154.27 %
Y / Y Revenue Change 8.21 % 17.84 % 39.33 % 29.56 % 53.56 %
Working Capital Per Revenue 1.04 1.21 1.13 1.05 0.92
Total Ranking # 3192 # 541 # 2021 # 2245 # 1495
Seq. Working Capital Change -35.18 % -6.52 % -6.88 % -5.66 % 135.33 %
Seq. Revenue Change 8.89 % 1.38 % 15.87 % -15.4 % 18.58 %


New: More APEN's historic Working Capital Per Revenue Ratios >>


See APEN Capital expenditures by quarter >> Back to APEN Financial Strength Comparisons >> See APEN Balance Sheets

Comment on APEN's Working Capital Per Revenue in the fourth quarter 2022
Apollo Endosurgery Inc 's Working Capital Per Revenue in the Q4 2022 sequentially fell to 1.04 but remained above Apollo Endosurgery Inc 's average.

Within Healthcare sector 78 other companies have achieved lower Working Capital Per Revenue during the Q4 2022. While Working Capital Per Revenue total ranking has deteriorated in the fourth quarter 2022, compared to previous quarter from 541 to 3192.
Working Capital Per Revenue Ranking
Within: No.
Industry # 15
Sector # 79
S&P 500 # 3192


Working Capital Per Revenue Statistics
High Average Low
1.26
0.72
0.28
(Mar 31 2018)   (Mar 31 2020)



Financial Statements
Apollo Endosurgery Inc 's Working Capital $ 53 Millions Visit APEN's Balance sheet
Apollo Endosurgery Inc 's Revenues $ 21 Millions Visit APEN's Income Statement
Where are APEN's Sales coming from? Visit APEN's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Dec 31 2022, within Healthcare Sector Working Capital Per Revenue
Intra cellular Therapies Inc   2.84 
Insmed Inc  2.84 
Regenxbio Inc   2.83 
G1 Therapeutics Inc   2.81 
Neurometrix Inc   2.77 
Rxsight Inc   2.69 
Delcath Systems Inc   2.68 
Outset Medical Inc   2.60 
Sonnet Biotherapeutics Holdings Inc   2.55 
Molecular Templates Inc   2.54 
Schrodinger Inc   2.53 
Immunogen inc   2.50 
Cryoport inc   2.46 
Electrocore Inc   2.45 
Cytek Biosciences Inc   2.45 
Ocular Therapeutix Inc   2.42 
Twist Bioscience Corporation  2.40 
Clearpoint Neuro Inc   2.40 
Avita Medical Inc   2.38 
Esperion Therapeutics inc   2.37 
Iteos Therapeutics Inc   2.37 
Deciphera Pharmaceuticals Inc   2.35 
Cytomx Therapeutics Inc   2.29 
Assure Holdings Corp   2.27 
Durect Corp  2.27 
Fortress Biotech Inc   2.27 
Nanostring Technologies Inc   2.23 
Ionis Pharmaceuticals Inc  2.22 
Ispecimen inc   2.16 
Neuropace Inc   2.16 
Date modified: 2023-03-31T17:15:09+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com